News about "Aurobindo Pharma"

Aurobindo's Subsidiary CuraTeQ Biologics Completes Phase 3 Clinical Study for Denosumab Biosimilar

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has successfully completed a pivotal clinical study of its denosumab biosimilar, evaluated against Amgen’s Prolia in 446 women with postmenopausal osteoporosis.

Aurobindo Pharma | 19/09/2025 | By Dineshwori |  140

Enzene, Aurobindo and Biocon Boost US Manufacturing with Major New Jersey Expansions

This month, three leading Indian firms — Enzene Biosciences, Aurobindo Pharma, and Biocon — have inaugurated major facilities in New Jersey, underscoring a growing trend of onshore investment by Indian pharma companies.

Aurobindo Pharma | 18/09/2025 | By Dineshwori

Aurobindo Pharma Expands Business in Malaysia with New Subsidiary

Aurobindo Pharma has announced the incorporation of a new wholly owned subsidiary, Aurobindo Pharma (Malaysia) SDN. BHD., through its subsidiary Helix Healthcare B.V.

Aurobindo Pharma | 18/09/2025 | By Dineshwori

US FDA Completes Inspection at Aurobindo Pharma's Telangana Unit

The inspection of Aurobindo Pharma’s Apitoria Unit-I facility, conducted from 21-29 August, 2025, concluded with five observations.

Aurobindo Pharma | 30/08/2025 | By Dineshwori |  203

Aurobindo Pharma Wins UK MHRA Approval for Dazublys Trastuzumab Biosimilar

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys, used in the treatment of HER2-positive breast and gastric cancers.

Aurobindo Pharma | 27/08/2025 | By Darshana |  106

CuraTeQ Biologics Receives UK MHRA Approval for Trastuzumab Biosimilar Dazublys

CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys.

Aurobindo Pharma | 26/08/2025 | By Dineshwori

Aurobindo Pharma USA To Acquire Lannett For USD 250 Million, Enter ADHD Treatment Space

Aurobindo Pharma USA Inc., has entered into a definitive agreement to acquire 100 percent membership interest in Lannett Company LLC from its parent company, Lannett Seller Holdco, Inc.

Aurobindo Pharma | 31/07/2025 | By Dineshwori |  138

Aurobindo Pharma Sets Up New US-Focused Step-Down Subsidiary to Boost Market Expansion

The new step-down subsidiary was incorporated on June 13, 2025, with an eye on expanding Aurobindo Pharma’s pharmaceutical products business in the US market, the Hyderabad-based company said in a regulatory filing.
<br />

Aurobindo Pharma | 17/06/2025 | By Darshana |  279

CuraTeQ Biologics Secures UK MHRA Approval for Bevqolva

Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins.

Aurobindo Pharma | 23/12/2024 | By Aishwarya |  325

Eugia Pharma Gets FDA Approval for Pazopanib Tablets

Aurobindo Pharma has announced that its wholly owned subsidiary company, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pazopanib Tablets, 200 mg.

Aurobindo Pharma | 06/12/2024 | By Aishwarya |  210